Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.755990
Title: The development of novel vorapaxar analogues as topical protease activated receptor-1 antagonists for the treatment of idiopathic pulmonary fibrosis
Author: Knight, E. F.
ISNI:       0000 0004 7428 9476
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2016
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
The overall aim of this project was to design and synthesise novel Protease Activated Receptor-1 (PAR-1) inhibitors in order to develop a novel treatment for Idiopathic Pulmonary Fibrosis (IPF). After finding the commercially available, allosteric PAR-1 inhibitor, “Q94” inactive and insoluble, focus switched to making novel vorapaxar analogues. A newly published synthetic route towards himbacine was successfully adapted to give vorapaxar analogues with a C-9-keto group. These were shown to have moderate potency against PAR-1 in a FLIPR calcium flux assay. After further synthetic route optimisation and investigation another novel vorapaxar analogue was identified. Compound (-)-94 was shown to be the most potent of the series of compounds tested, achieving an IC50 of 27 nM. In the same assay vorapaxar gave an IC50 of 13 nM. This makes (-)-94 a novel, potent, PAR-1 inhibitor worthy of further investigation and development as a potential IPF drug.
Supervisor: Caddick, S. Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.755990  DOI: Not available
Share: